Close Menu

Rapamycin Improves Vascular Remodelling in a Controlled Rat Model of Monocrotaline-induced Pulmonary Hypertension

DOI: 
10.7727/wimj.2015.222

ABSTRACT

Objective: Pulmonary arterial hypertension (PAH) is a serious disease characterized by progressive elevation of pulmonary arterial resistance, leading to right ventricular failure and death. We aimed to evaluate the effect of rapamycin (RAPA), a potent cell-cycle inhibitor, on exercise capacity, right ventricular hypertrophy, and pulmonary vascular remodeling.

Methods: Thirty-nine nine-week-old male Wistar rats (160–240 g) were divided into three groups: the control (n = 10), PAH control (n = 15), and PAH-RAPA (n = 14) groups. On the first day, 60 mg/kg monocrotaline was injected intraperitoneally to induce PAH in the PAH control and PAH-RAPA groups. On the 21st day, 3 mg/kg/day RAPA was started orally, and the animals were followed for 35 days. On the 35th day, the exercise capacity of the rats was analyzed through a modified forced swimming test. After measuring right ventricular systolic pressure using an open-chest method, the heart and lungs were excised and analyzed histopathologically for right ventricular hypertrophy and pulmonary vascular remodeling.

Results: RAPA treatment provided limited, but not significant, improvements in exercise capacity, right ventricular systolic pressure, and right ventricular hypertrophy. However, there was significant recovery in pulmonary artery muscular layer thickness with RAPA treatment (p = 0.049). On the 35th day, the mortality rate was 0% in the control group, 53.1% in the PAH control group, and 42.9% in the PAH-RAPA group. No statistically significant decrease was observed in mortality rates with RAPA treatment (p = 0.16); however, a significant recovery was noted in terms of median life span (p = 0.006).

Conclusions: PAH is a progressive disease that is not curable with current therapies. RAPA may have the potential reverse vascular remodeling and prolong life expectancy in cases of pulmonary hypertension.

Accepted: 
18 May, 2015
PDF Attachment: 
e-Published: 13 Aug, 2015

Disclaimer

Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.

Top of Page